Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study

BACKGROUND: Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody (mAb), but there are no efficacy data so far. In this real-world analysis, we assessed the treatment response to a CGRP-mAb in...

Descripción completa

Detalles Bibliográficos
Autores principales: Overeem, Lucas Hendrik, Peikert, Andreas, Hofacker, Maxi Dana, Kamm, Katharina, Ruscheweyh, Ruth, Gendolla, Astrid, Raffaelli, Bianca, Reuter, Uwe, Neeb, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988456/
https://www.ncbi.nlm.nih.gov/pubmed/34644203
http://dx.doi.org/10.1177/03331024211048765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988456/
https://www.ncbi.nlm.nih.gov/pubmed/34644203
http://dx.doi.org/10.1177/03331024211048765

Ejemplares similares